Transgenomic secures exclusive license from Montefiore for cancer predictive markers
Links shared publicly online about this topic.
- 263total visits
Transgenomic secures exclusive license from Montefiore for cancer predictive markers
Transgenomic, Inc. announced today that it has acquired an exclusive worldwide license to Montefiore Medical Center's patent application, "Method of Determining the Sensitivity of Cancer Cells to EGFR Inhibitors including cetuximab, panitumumab and erlotinib".
View full resource at news-medical.net
Tags: Cancer, Colorectal Cancer Medication, Erbitux, Vectibix, Medical
Most Recently Shared on May 27, 2011 at 10:44 pm By:
Oncology News: Transgenomic secures exclusive license from Montefiore for cancer predictive markers: Transgenomi... http://bit.ly/mx3kWW
Also Shared By:
Advertisement
News-Medical.Net
@NewsMedical
Transgenomic secures exclusive license from Montefiore for cancer predictive markers: Transgenomic, Inc. announc... http://bit.ly/mx3kWW
1 year ago...